Lantern Pharma is trading 5.5% down now at $0.60, with no confirmed cause for the October 26, 2026 decline.
- Its investor-relations news page lists releases dated October 8 and earlier; no new catalyst for the session surfaced.
- Broader markets were higher, and an earlier report also noted no clear company-specific catalyst.